Cystic fibrosis gene therapy - Inex Pharmaceuticals

Drug Profile

Cystic fibrosis gene therapy - Inex Pharmaceuticals

Latest Information Update: 16 Dec 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Inex Pharmaceuticals Corporation
  • Developer Inex Pharmaceuticals Corporation; The Hospital for Sick Children
  • Class Gene therapies
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cystic fibrosis

Most Recent Events

  • 16 Dec 1998 Discontinued-Preclinical for Cystic fibrosis in Canada (Unknown route)
  • 28 Oct 1997 Preclinical development for Cystic fibrosis in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top